Side-by-side · Research reference

PinealonvsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED12/36 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

Pinealon

Pineal-derived · Neuroprotective

5–10 mgPer cycle doseKhavinson 2014

HumanMechanisticKhavinson 2014

HoursHalf-life (est)

SQ or IM · Daily for 10 days · 1-2×/year

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

Pinealon

Vilon

Primary target

Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014

Immune cell differentiation pathways, chromatin modification

Pathway

Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

—

Unknown — no HPA/HPG axis data

Origin

Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

Pinealon

Vilon

Standard dose

5–10 mg / day for 10 daysKhavinson 2014

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Frequency

Once daily during cycle

Unknown — literature does not specify chronic administration protocols

Lower / starter dose

2.5 mg / day

—

Evidence basis

Russian clinical trials + in vitroKhavinson 2014

Mouse / in vitro only

Duration

10-day cycles, 1–2× per year

Not characterised in humans

Reconstitution

Bacteriostatic water

—

Timing

No specific time

—

Half-life

Hours

Not published — dipeptides typically <10 min plasma t½

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

04Side Effects & Safety

Parameter

Pinealon

Vilon

Injection site reaction

Mild irritation

—

Long-term safety

Limited Western data

—

Pregnancy / OB

Avoid

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

Pinealon

·Pregnancy / breastfeeding

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

Pinealon

·Active malignancy (theoretical via gene expression modulation)

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

Pinealon

Vilon

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Injection site

SQ — abdomen preferred.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Daily during cycle, any time.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

Pinealon

+ Epitalon

Moderate

View Epitalon →

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon: 5–10 mg SQ · daily × 10 days
Epitalon: 5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit: Neuroprotection + telomere preservation

Khavinson 2014 Khavinson 2003

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020